Composition and method for treatment of diabetes
AssigneeBioKier, Inc.
InventorJerzy Ryszard Szewczyk
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating diabetes Type II by oral delivery of butyric acid, and a DPP-IV inhibitor such as vildagliptin only to the ileum bypassing the stomach, duodenum and jejunum.
Claims5
An oral pharmaceutical composition for use in a human comprising:
- composition for use in a human comprising:
- a) a single agent for inducing release of a gut hormone from an L-cell, wherein the single agent is butyric acid in an amount from about 100 mg to about 2 gm;
- and
- b) a DPP-IV inhibitor of from about 0.01 mg/kg to about 1 mg/kg in an amount that is about 1% to about 10% of the oral dosage of the DPP-IV inhibitor normally delivered to the stomach of the human, sufficient to inhibit the degradation of the gut hormone in the ileum and in the portal circulation;
- wherein the agent and the inhibitor are formulated together for simultaneous delivery to and release in the ileum using a ileum-targeted delivery system which bypasses the stomach, duodenum and jejunum upper digestive system. The composition according to claim 1 wherein the DPP-IV inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, and berberine.
In another embodiment of the present invention, there is a method of treating the condition of diabetes mellitus Type II in a human comprising:
- a) selecting a single agent causing gut hormone secretion from L-cells, wherein the agent is butyric acid in an amount from about 100 mg to about 2 gm;
- b) selecting a DPP-IV inhibitor of from about 0.01 mg/kg to about 1 mg/kg consisting of an amount that is from about 1% to about 10% of the oral dosage of the DPP-IV inhibitor delivered to the stomach sufficient to inhibit the degradation of the gut hormone in the ileum and in the portal circulation;
- and
- c) administering to the individual the agent formulated in combination with the DPP-IV inhibitor orally using a ileum-targeted delivery system, which bypasses the stomach, duodenum and jejunum and causes simultaneous ileum delivery and release of the agent and inhibitor.
The method according to claim 4 wherein the DPP-IV inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, and berberine.
The method according to claim 5 wherein the inhibitor is vildagliptin.
Dependencies are inferred from the claim text.